@misc{cogprints8934,
          volume = {11},
          number = {4(5)},
           month = {January},
          author = {R Bhise and S Purohit and D Lokanatha and L Jacob and TM Suresh and K Govind Babu and S Babu and KC Lakshmaiah},
          editor = {Dr Srinivas Kakkilaya},
           title = {Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate.},
       publisher = {Kakkilaya BS},
            year = {2013},
         journal = {Online Journal of Health and Allied Sciences},
        keywords = {Chronic myeloid leukemia; Imatinib; Variant translocation},
             url = {http://cogprints.org/8934/},
        abstract = {Objective: To evaluate the efficacy of imatinib in chronic myeloid leukemia patients with variant translocations. Methods: Forty eight chronic myeloid leukemia patients carrying variant translocations and treated with imatinib at our institute were considered for the study. Survival and response rates were evaluated. Results: The median follow up was 48 months(m). Forty three (89.58\%) patients achieved complete hematologic response. Thirty one (64.58\%) patients achieved complete cytogenetic response and 19(39.58\%) achieved major molecular response anytime during their follow up period. Only 18.75\% of the patients achieved complete cytogenetic response and major molecular response within the stipulated time frames.The estimated overall survival at 48 m median follow up was 81.2\%.The progression free survival was also 81.2\% and the event free survival was 79.1\%.There was no significant survival difference between low vs intermediate and high risk sokal group. Conclusion: We report suboptimal responses to imatinib in chronic myeloid leukemia with variant translocations. Further studies with imatinib and the newer more active drugs dasatinib and nilotinib are justified.}
}

<script src="//archive-bar.soton.ac.uk/archive-bar.js"></script>